Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS)
CNY31.78
+3.55 (+12.58%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
Biology Incubator Building 2 518057
Shenzhen, CN
Shenzhen, CN
CEO
Xian-Ping Lu
Website
chipscreen.com
IPO
2019-08-12
ISIN CNE100003LW0
Description
Established in 2001 and headquartered in Shenzhen, China, Chipscreen Biosciences specializes in the discovery, development, and commercialization of innovative small-molecule pharmaceuticals. The company cultivates a pipeline of novel drug candidates and precursor compounds, all of which are progressing through diverse research phases and are protected by extensive global intellectual property rights. Its key therapeutic areas of focus encompass oncology, metabolic disorders, and autoimmune conditions.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY31.78
+3.55 (+12.58%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
0.68
Float Shares
273.55M
Free Float %
61.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.74% | -5.00% | -13.31% | -16.72% | -3.35% | -7.08% | +37.12% | +19.24% | -28.93% | -71.51% | -71.51% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
31.78
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.32
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+38.2% ★ Q1'26: +58.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+146.4% ★ Q1'26: +241.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-6.7% Q1'26: -29.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+5.6% Q1'26: +14.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.3% Q1'26: +6.5% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q1'26: +4.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×11.16× Q1'26: 8.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
269.47M
est: 336.00M (-19.8%)
|
430.45M
est: 515.00M (-16.4%)
|
529.94M
est: 607.00M (-12.7%)
|
523.71M
est: 615.00M (-14.8%)
|
657.95M
est: 706.00M (-6.8%)
|
909.54M
est: 910.00M (-0.1%)
|
1.28B
1.28B – 1.28B
+40.7% YoY
|
1.75B
1.75B – 1.75B
+36.8% YoY
|
2.70B
2.70B – 2.70B
+54.1% YoY
|
| EBITDA |
48.30M
est: -11.11M (+534.6%)
|
37.09M
est: -17.03M (+317.8%)
|
72.35M
est: -20.08M (+460.3%)
|
173.93M
est: -20.34M (+955.0%)
|
-5.81M
est: 93.78M (-106.2%)
|
107.49M
est: 120.87M (-11.1%)
|
170.12M
170.12M – 170.12M
+40.7% YoY
|
232.70M
232.70M – 232.70M
+36.8% YoY
|
358.53M
358.53M – 358.53M
+54.1% YoY
|
| EBIT |
37.23M
est: -31.86M (+216.9%)
|
23.46M
est: -48.84M (+148.0%)
|
35.42M
est: -57.56M (+161.5%)
|
131.90M
est: -58.32M (+326.2%)
|
-62.46M
est: 47.18M (-232.4%)
|
50.84M
est: 60.82M (-16.4%)
|
85.60M
85.60M – 85.60M
+40.7% YoY
|
117.08M
117.08M – 117.08M
+36.8% YoY
|
180.39M
180.39M – 180.39M
+54.1% YoY
|
| Net Income |
31.05M
est: 61.20M (-49.3%)
|
21.96M
est: 53.04M (-58.6%)
|
17.48M
est: 20.40M (-14.3%)
|
88.84M
est: 281.53M (-68.4%)
|
-114.57M
est: -85.67M (-33.7%)
|
51.08M
est: 50.99M (+0.2%)
|
142.78M
142.78M – 142.78M
+180.0% YoY
|
265.17M
265.17M – 265.17M
+85.7% YoY
|
350.84M
350.84M – 350.84M
+32.3% YoY
|
| SGA |
164.04M
est: 214.43M (-23.5%)
|
287.72M
est: 328.66M (-12.5%)
|
316.78M
est: 387.38M (-18.2%)
|
364.33M
est: 392.48M (-7.2%)
|
408.13M
est: 405.32M (+0.7%)
|
262.28M
est: 522.43M (-49.8%)
|
735.30M
735.30M – 735.30M
+40.7% YoY
|
1.01B
1.01B – 1.01B
+36.8% YoY
|
1.55B
1.55B – 1.55B
+54.1% YoY
|
| EPS |
0.08
est: 0.15 (-49.5%)
|
0.05
est: 0.13 (-58.7%)
|
0.04
est: 0.05 (-14.0%)
|
0.22
est: 0.69 (-68.1%)
|
-0.28
est: -0.21 (-33.3%)
|
0.13
est: 0.13 (+4.0%)
|
0.35
0.35 – 0.35
+180.0% YoY
|
0.65
0.65 – 0.65
+85.7% YoY
|
0.86
0.86 – 0.86
+32.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
274.67M
OE per share TTM
0.67
Owner's Yield
2.38%
Maintenance CapEx ratio
123.89%
Maint CapEx / Avg PPE
143.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 15 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 398.3K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 30.4K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 13.5K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.50M | 0.06% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 48.2K | 0.39% |
| 6 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 42.7K | 0.29% |
| 7 | Vanguard ESG International Stock ETF VSGX | 0.00% | 19.1K | 0.10% |
| 8 | Vanguard Total International Stock ETF VXUS | 0.00% | 1.56M | 0.05% |
| 9 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 2.4K | 0.22% |
| 10 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 7.3K | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
48.1K
Shares Outstanding
442.94M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Desi Pan | Vice President, Deputy GM, Chief Scientific Officer and Head of the Early Research & Development Center | — | — |
| Ji-Hui Yi | Vice President of Sales & Marketing | — | male |
| Jian-Xun Li BA.CFA | Co-President, Head of Finance & Director | — | male |
| Leming Shi | Co-Founder | — | — |
| Liangji She | Senior Vice President & Head of the Commercial Segment | — | male |
| Ou Hai | Vice President, Deputy GM, Secretary of the Board, Head of Legal & Intellectual Property Department and Director | — | female |
| Weiming Hu | Co-Founder | — | — |
| Xian-Ping Lu | Founder, Chairman, GM, Chief Executive Officer & President | — | — |
| Zhi-Bin Li | Senior Vice President and Head of Product Development & Production | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688321.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
